Graduate Programs

Faculty Research Mentors


Program Affiliation: M.S. in Pharmaceutical Sciences
(802) 735-2615 | 

Dr. Balaz’s research is oriented towards the development of experimental and computational methods for determining drug disposition and receptor binding. In disposition, his lab performs experimental measurements using (1) surrogate phases to find structural determinants of transbilayer transport rates and accumulation in membranes and triglyceride phases, and (2) binding to prevalent human proteins such as albumin and extracellular matrix components. The data is used to develop structure-based models for predicting the volume of distribution and other pharmacokinetic characteristics. One of the major goals of this work is to find ways to tailor drug structures for limited distribution, thereby reducing the cytotoxicity of drugs such as those used in treating some cancers or arthritis.

Christopher Cioffi, Ph.D.
Christopher Cioffi, Ph.D. (Albany)

Assistant Professor
Program Affiliation: M.S. in Pharmaceutical Sciences
(518) 694-7224 |                                                                             

Dr. Cioffi is a medicinal chemist with extensive experience in integrated drug discovery working on research programs in support of large pharma, biotech, academic, and NIH collaborations. He has made significant drug design contributions to programs spanning multiple therapeutic indications (e.g., dyslipidemia, irritable bowel syndrome, CNS, and ophthalmology) and has helped advance drug candidates into pre-clinical development and clinical trials. In 2018, Dr. Cioffi was named co-principal investigator on a three-year, $1.45 million NIH research grant aimed at developing novel drug compounds for treating Age-related Macular Degeneration (AMD), a leading cause of vision loss in people age 50 and older.


Associate Professor
Program Affiliation: M.S. in Pharmaceutical Sciences
(518) 694-7387 |

Dr. Dearborn’s research focuses on development neurobiology in the fruit fly (Drosophila) in three primary areas: 1) The elucidation of vitamin D3 up-regulated protein 1 (VDUP1) tumor suppressor function during brain development, including VDUP1’s role in neural stem cell biology, 2) Hedgehog (Hh)-dependent regulation of VDUP1 in cell proliferation, including how tumor cell-specific differences in Hh signaling affect pharmacological treatment strategies, and 3) Molecular characterization of Eph receptor signaling pathways, which regulate axon guidance, vascular growth, and tumorigenesis. The lab emphasizes molecular-genetic approaches in these studies, each with clinical and translational relevance.

KAREN C. GLASS, PH.D. (Vermont)

Associate Professor
(802) 735-2636 |
Program Affiliation: M.S. in Pharmaceutical Sciences

Dr. Glass' laboratory investigates how epigenetic mechanisms regulate diverse cellular activities. High field Nuclear Magnetic Resonance (NMR) spectroscopy, X-ray crystallography, and biochemical and molecular biology approaches are utilized to determine the three-dimensional structures and functions of chromatin binding proteins implicated in human diseases such as leukemia, heart disease, and cancer. Ultimately, these studies will lead to the identification of new therapeutic targets, more specific treatment strategies, and better overall outcomes for patients. Click the following link to read about Dr. Glass' latest NIH-funded grant.

MARTHA A. HASS, PH.D. (Albany)

Associate Professor and Director of Research
(518) 694-7238 |
Program Affiliation: M.S. in Pharmaceutical Sciences

Dr. Hass’ research integrates synthetic organic chemistry, pharmaceutical formulation and stability, biochemical assays, medicinal chemistry, and pharmacology. Her laboratory provides training opportunities for students in the areas of drug synthesis, pharmaceutical formulation, topical drug delivery, and assessment of drug efficacy. A major area of focus is the synthesis and activity of new drugs for use as topical agents to treat skin diseases. One group of novel co-drugs is designed to replenish natural antioxidants in the skin for enhanced and extended photoprotection relative to existing topical products. Other topical agents under development utilize the co-drug approach to target hyperproliferation of keratinocytes and inflammation associated with psoriasis.

Kideok Jin, Ph.D.
Kideok Jin, Ph.D. (ALBANY)

Assistant Professor
(518) 694-7175 |
Program Affiliation: M.S. in Pharmaceutical Sciences

About 70% of estrogen receptor (ER) positive breast cancers have a significantly reduced risk of invasive breast cancer through the use of various endocrine therapies. Despite the relative safety and significant anti-neoplastic and chemopreventive activities of tamoxifen and aromatase inhibitors, many initially responsive breast tumors develop resistance and ultimately recur. My current research is to investigate the secretome leading to the endocrine resistance in crosstalk between endocrine resistant breast cancer and tumor microenvironment. The long-term mission of my laboratory is to understand the steps of the endocrine resistant process in order to develop therapeutic approaches to prevent and treat endocrine resistant breast cancer effectively. The ultimate goal of my research is to bring therapies into the clinic that will improve the survival of metastatic breast cancer patients.

Timothy LaRocca, Ph.D.
Timothy LaRocca, Ph.D. (Albany)

Assistant Professor 
Tel: (518) 694-7332 |
Program Affiliation: M.S. in Molecular Biosciences

Dr. LaRocca’s research interest lies primarily in the mechanisms of eukaryotic programmed cell death or PCD. This includes the processes of apoptosis, necroptosis, and the molecular switches that balance the two pathways. Dr. LaRocca is particularly interested in the role of glucose in driving PCD. He is actively investigating the mechanism of hyperglycemic cell death and its role in the exacerbation of ischemic brain injury (stroke). A second project in his lab is an NIH-funded grant aimed at improving understanding of a type of red blood cell death called necroptosis and exploring ways to influence this process. Results from this work could one day lead to improved treatments for patients suffering from bacterial blood infections and other blood related disorders. 


(518) 694-7168 |
Program Affiliations: M.S. in Pharmaceutical Sciences, M.S. in Molecular Biosciences

The long term research goal of Dr. Malik’s laboratory is to understand the complexities of host pathogen interactions for the development of improved prophylactics and therapeutics against important bacterial infections. She has a three-year grant by the National Institutes of Health to investigate the mechanisms by which Francisella tularensis, a category A biothreat agent survives inside the immune cells and suppresses the protective immune responses. A second area of focus is investigating the molecular mechanisms leading to the development of antibiotic resistance in methicillin resistant Staphylococcus aureus (MRSA) strains. Click the following PubMed link for additional information on research projects taking place in Dr. Malik's lab.


Professor, Vice Provost for Research
Chairman of ACPHS Pharmaceutical Research Institute
(518) 694-7397 |
Program Affiliations: M.S. in Pharmaceutical Sciences, M.S. in Molecular Biosciences 

Dr. Mousa's current research interest is focused on advancing novel concepts in therapeutic and diagnostic targets through the exploration of the role of cell adhesion molecules and extracellular matrix proteins, angiogenesis, thrombosis, and inflammation modulation in health and diseases. To this end, enabling technologies including nanotechnology, biotechnology, pharmacotherapy, and stem cells serve as key catalysts in the discovery of novel therapeutics and diagnostics for the treatment and prevention of various diseases including oncological, cardiovascular, neurological, ophthalmological, inflammatory, and other vascular disorders. Visit the Pharmaceutical Research Institute website to learn more about current projects and initiatives.


Associate Professor
(518) 694-7883 |
Program Affiliation: M.S. in Pharmaceutical Sciences

Dr. Musteata's research interests include the development of miniaturized analytical technology for
pharmacokinetic studies and therapeutic drug monitoring, with the purpose of creating personalized therapeutic
devices that integrate chemical analysis, decision, and drug delivery.

Manish B. Shah, Ph.D.
Manish B. Shah, Ph.D. (Albany)

Assistant Professor
(518) 694-7343 |
Program Affiliation: M.S. in Molecular Biosciences; M.S. in Pharmaceutical Sciences

Work in Dr. Shah's laboratory involves structural biology. He is currently investigating genetic polymorphisms in drug metabolizing Cytochrome P450 (CYP) enzymes using structural and biophysical methods. CYP's constitute the major enzyme family in drug metabolism, and single nucleotide polymorphisms with amino acid substitutions are important contributors to interindividual variability in drug response. In brief, recombinant protein expression and purification are carried out in the laboratory in order to produce the quantities of CYP protein necessary for crystallization. The crystallographic data is collected remotely, and the three dimensional structure of the protein is then elucidated using computational tools.

Nicole Shakerley, PH.D., MB(ASCP)CM
Nicole Shakerley, PH.D., MB(ASCP)CM (Albany)

Assistant Professor
(518) 694-7281 |
Program Affiliation: M.S. in Molecular Biosciences

Dr. Shakerley’s research interests include the study of Acinetobacter baumannii bacterium, a gram negative opportunistic pathogen that presents not only a nosocomial threat, but specifically impacts military personnel deployed to overseas theatres of operation. Currently, multidrug-resistant Acinetobacter species account for more than 7,000 infections in the United States per year which may be exacerbated by the pathogen’s innate ability to evade host immune defenses. One of the major areas of focus for her lab is the development of novel therapeutic strategies to combat antibiotic resistant nature of this pathogen.

H. John Sharifi, Ph.D.
H. John Sharifi, Ph.D. (Albany)

Assistant Professor
(518) 694-7299 |
Program Affiliation: M.S. in Molecular Biosciences

For the vast majority of virus-types found on Earth, human cells are successful at defending themselves from invasion. However, many viruses that are significant human pathogens have evolved mechanisms to counter cellular defenses and thus enable disease spread. The majority of Dr. Sharifi’s research is focused on this evolutionary “arms race” between viruses and host-cells which has included deeper exploration of the HIV virus. This work has also helped lead to a better understanding of normal cell biology, which has subsequently opened doors to new questions and opportunities for student-centered research.


Assistant Professor
(518) 694-7116 |
Program Affiliations: M.S. in Molecular Biosciences, M.S. in Pharmaceutical Sciences

Dr. Shi’s research interests are mainly focused on understanding the molecular basis of disease pathogenesis by using advanced molecular biology, virology, molecular genetics, and bioinformatics approaches. Methods used in his lab include a) HIV-1 infectious molecular clone, recombinant virus, and reporter gene technologies to study HIV phenotypes such as infection and replication; b) HIV-1 single genome amplification, sequencing and bioinformatics tools to understand genotype changes and their association with disease progression. Another major area of interest in Dr. Shi’s lab is the design and development of diagnosis assays for detecting infectious diseases, monitoring disease progression, and managing treatments.

Vir Singh
Vir Singh, PH.D (ALBANY)

Assistant Professor
(518) 694-7368 |
Program Affiliation: Department of Basic and Clinical Sciences

Dr. Singh has an extensive scientific background in studying molecular mechanisms associated with HIV pathogenesis, genomic imprinting, molecular biology and mouse models of disease. Dr. Singh’s research interests include investigating the underlying molecular mechanisms involved in- i) HIV associated neurological disorder, ii) HIV latency, and iii) Viral infection induced developmental defects. Currently, Dr. Singh’s lab is focused at investigating two projects that come under NIH HIV/AIDS high priority research topics. Project 1: To investigate the consequences of HIV (Human Immunodeficiency Virus) mediated downregulation of Sonic hedgehog (Shh) signaling on brain homeostasis with specific focus on aberrant communication between astrocytes and other brain-resident cells (brain endothelial cells, pericytes, microglia and neurons). Project 2: To characterize select noncoding RNAs for their potential to establish HIV latency via- i) mediating Interferon signaling, and ii) regulating expression of HIV genome by epigenetic mechanisms. Successful completion of these studies will identify novel targets to alleviate HIV pathogenesis as well as pave the way towards HIV cure.


Associate Professor
(518) 694-7308 |
Program Affiliation: M.S. in Pharmaceutical Sciences

VDUP-1 (TBP-2) is a protein whose expression is decreased in tumors and increased following treatment with Vitamin D. VDUP-1 functions as an inhibitor of thioredoxin, which interacts with a number of transcription factors. Dr. Voigt is currently investigating the role of VDUP-1 in regulation of transcription factor activity and cell proliferation/differentiation in different cell types.

ERIC YAGER, PH.D. (Albany)

Assistant Professor
(518) 694-7110 |
Program Affiliation: M.S. in Molecular Biosciences

Research in Dr. Yager’s laboratory is focused on understanding how the body regulates inflammatory responses during flu infection. Recent studies have established a critical role for the multi-protein cytosolic NLPR3 inflammasome complex in host defense and pathophysiology during flu infection. Specifically, Dr. Yager and his team are investigating how NLRP3 inflammasome activation and resultant inflammatory cytokine secretion are regulated on a molecular level to favor host protection over immunopathology. Other areas of research include the identification of novel targets for the development of new anti-viral drugs to combat flu infection and the role of viral-induced inflammation in the etiology and pathogenesis of autism spectrum disorder.

Haian Zheng, Ph.D. (ALBANY)
Haian Zheng, Ph.D. (ALBANY)

Associate Professor
(518) 694-7895 |
Program Affiliation: M.S. in Pharmaceutical Sciences

Dr. Zheng’s research group is interested in the design and evaluation of Complex Drug Products (CDP) that are made of botanicals, peptides, and proteins from nature. Interdisciplinary technologies and translational strategies are used to ensure pharmaceutical quality, elucidate mechanisms of action, and evaluate clinical benefits and risks. These efforts can help empower regulatory decisions and enable patient-centric product design. Current projects in the lab focus on assessing the risks and benefits of medical cannabis products. This includes studying the effects of botanical and endogenous cannabinoids on the brain and the blood brain interface (BBI) as well as investigating the endocannabinoid system (ECS) on drug delivery barriers.